Literature DB >> 9185588

Transactivation of prothymosin alpha and c-myc promoters by human papillomavirus type 16 E6 protein.

T Kinoshita1, H Shirasawa, Y Shino, H Moriya, L Desbarats, M Eilers, B Simizu.   

Abstract

The human papillomavirus type 16 E6 protein exerts a transforming activity through inactivation of tumor suppressor p53. Recently E6 has been shown to have additional transforming activities independent of p53. E6 is able to transactivate or repress several specific viral promoters. However, underlying molecular mechanisms and cellular target genes for the activity are not well understood. Using a differential hybridization technique, we identified the prothymosin alpha gene as a cellular target of E6 transactivation. E6 was able to transactivate the prothymosin alpha promoter in H358 cells lacking p53 and in C33A cells harboring a mutant p53 allele. Disruption of the E-box in intron 1 of the prothymosin alpha promoter abolished the responsiveness to E6. Then we determined if E6 up-regulates the expression of Myc, by which the prothymosin alpha promoter is transactivated through the E-box. We found that E6 is also able to transactivate the c-myc promoter in H358 cells and in C33A cells. These results suggest that E6 is able to transactivate the c-myc promoter independently of p53, and that the prothymosin alpha promoter is subsequently transactivated by Myc.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185588     DOI: 10.1006/viro.1997.8536

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites.

Authors:  S T Oh; S Kyo; L A Laimins
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Genetic variations in human papillomavirus and cervical cancer outcomes.

Authors:  Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister
Journal:  Int J Cancer       Date:  2019-01-04       Impact factor: 7.396

Review 3.  Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression.

Authors:  Oishee Chakrabarti; Sudhir Krishna
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

Review 4.  Human papillomavirus infection with particular reference to genital disease.

Authors:  C Sonnex
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

5.  Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells.

Authors:  Y Liu; J J Chen; Q Gao; S Dalal; Y Hong; C P Mansur; V Band; E J Androphy
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 6.  Biology of human papillomaviruses.

Authors:  H R McMurray; D Nguyen; T F Westbrook; D J McAnce
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

7.  Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex.

Authors:  Lindy Gewin; Hadley Myers; Tohru Kiyono; Denise A Galloway
Journal:  Genes Dev       Date:  2004-09-15       Impact factor: 11.361

9.  Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity.

Authors:  L V Ronco; A Y Karpova; M Vidal; P M Howley
Journal:  Genes Dev       Date:  1998-07-01       Impact factor: 11.361

10.  Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses.

Authors:  Ruprecht Kuner; Markus Vogt; Holger Sultmann; Andreas Buness; Susanne Dymalla; Julia Bulkescher; Mark Fellmann; Karin Butz; Annemarie Poustka; Felix Hoppe-Seyler
Journal:  J Mol Med (Berl)       Date:  2007-06-23       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.